Kiniksa Pharmaceuticals, Ltd. (KNSA) is a global biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic treatments for patients living with debilitating diseases. The firm has built a dynamic portfolio focused on autoinflammatory and autoimmune conditions that is reflective of their comprehensive approach to addressing significant unmet medical needs.
The company was co-founded in 2015 by Sanj K. Patel, former President and CEO of Synageva BioPharma Corp., which was acquired by Alexion Pharmaceuticals for $8.4 billion. Headquartered in Hamilton, Bermuda, and with locations in the U.S., Kiniksa has a seasoned leadership team with extensive industry experience in developing and commercialising drugs.
Kiniksa's primary entities in the research and development pipeline include Rilonacept, which targets Cryopyrin-Associated Periodic Syndromes (CAPS); Vixarelimab, designed to treat prurigo nodularis and chronic spontaneous urticaria; Mavrilimumab, a potential treatment for giant cell arteritis and Takayasu arteritis; and Arcalyst, which is aimed at treating certain autoinflammatory conditions.
An essential asset of Kiniksa’s business model is its patient-centric approach. The company endeavors to understand the patient’s journey—clinical, economic, and humanistic—by patient segment, disease severity, and current treatment practice to design and implement thoughtful clinical development strategies.
In terms of financial performance, Kiniksa Pharmaceuticals, Ltd. operates as a publicly traded company on the NASDAQ Exchange under the ticker symbol 'KNSA'. Despite the inherent risks involved in the pharmaceutical industry and the challenges of drug development, the company continues to make significant strides. As of late 2021, their market capitalization stands at over $1 billion, showcasing investor confidence in their science-driven approach.
In summary, Kiniksa Pharmaceuticals, Ltd. is an innovative biopharmaceutical company that is dedicated to robust research and development to bring novel treatments to market. The firm’s strategic focus on inflammatory and autoimmune conditions offers the potential to significantly benefit patients suffering from these devastating diseases. Leveraging its experienced team and a diverse pipeline of promising therapeutics, Kiniksa is positioned to continue playing a pivotal role in improving patient outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Kiniksa Pharmaceuticals International (KNSA) CEO Sanj Patel sold 151,300 shares for $14.3 million at an average price of $94.71 under a 10b5-1 plan. This transaction occurred after he exercised 145,763 options at $17.92. Following these transactions on November 4, 2026, Patel indirectly holds 774,500 shares.
Kiniksa Pharmaceuticals International, plc (KNSA) reported strong Q3 2026 results, with earnings of $0.56 per share significantly beating the Zacks Consensus Estimate of $0.32, and revenues of $285.97 million also surpassing estimates. The company has a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market. KNSA shares have seen a substantial increase of 76.9% year-to-date, outperforming the S&P 500.